Search results for "Vascular endothelial growth factor"

showing 10 items of 320 documents

The role of targeted therapy for gastrointestinal tumors

2014

Abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinic…

SorafenibOncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyReceptor ErbB-2Hepatocellular carcinomaSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsNeuroendocrine tumorsTargeted therapyTargeted therapychemistry.chemical_compoundNeuroendocrine tumorTrastuzumabInternal medicineRegorafenibmedicineHumansGastrointestinal tumorsMolecular Targeted TherapyProtein Kinase InhibitorsGastrointestinal NeoplasmsEverolimusHepatologySunitinibbusiness.industryColorectal cancer; Gastric cancer; Gastrointestinal tumors; Hepatocellular carcinoma; Neuroendocrine tumors; Targeted therapy; Hepatology; GastroenterologyGastrointestinal tumorGastroenterologyCancermedicine.diseaseColorectal cancerErbB ReceptorsReceptors Vascular Endothelial Growth FactorchemistryHuman medicineNeuroendocrine tumorsbusinessGastric cancermedicine.drug
researchProduct

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

2015

Abstract: Introduction: Angiogenesis is fundamental for tumor development and progression. Hence, anti-angiogenic drugs have been developed to target VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs) have been developed over the years and others are still under investigation, each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of the cardiac side-effects of each drug and the magnitude of their expression and frequency can lead to a specific approach. Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs and the pathophysiological mechanisms leading to cardiotoxicity, followed by close examination of the most important drugs i…

SorafenibOncologymedicine.medical_specialtymedicine.drug_classSettore MED/06 - Oncologia MedicaAntineoplastic AgentsPharmacologyVandetanibModels BiologicalTyrosine-kinase inhibitorPazopanibchemistry.chemical_compoundInternal medicineRegorafenibNeoplasmsmedicineHumansPharmacology (medical)Molecular Targeted TherapyProtein Kinase Inhibitorstyrosine kinase inhibitor cardiac toxicityNeovascularization PathologicSunitinibbusiness.industryPharmacology. TherapyCancerHeartGeneral MedicineDrugs InvestigationalProtein-Tyrosine Kinasesmedicine.diseaseAxitinibReceptors Vascular Endothelial Growth FactorchemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Synthesis and biological evaluation of cyclic derivatives of combretastatin A-4 containing group 14 elements

2018

Several tricyclic compounds inspired by the structure of combretastatin A-4 and bearing group 14 elements have been synthesized by homocoupling lithiated aryl fragments followed by ring-closing metathesis. These tricyclic compounds and their diolefin precursors were evaluated for their antiproliferative action on the tumor cell lines HT-29, MCF-7, HeLa and A-549 and on the non-tumor cell line HEK-293. In addition, their effects on the cell cycle were also measured. The tricyclic compounds show antiproliferative activity similar to that of combretastatin A-4, even though they are not so active in arresting the cell cycle. However, some diolefin precursors are able to cause accumulation of ce…

Stereochemistry010402 general chemistry01 natural sciencesBiochemistryHeLachemistry.chemical_compoundTubulinCell Line TumorNeoplasmsStilbenesHumansPhysical and Theoretical ChemistryCell ProliferationCombretastatin A-4Tube formationCombretastatinchemistry.chemical_classificationbiology010405 organic chemistryArylCell CycleOrganic ChemistryCell cyclebiology.organism_classificationAntineoplastic Agents PhytogenicVascular Endothelial Growth Factor Receptor-20104 chemical sciencesHEK293 CellschemistryCell cultureDrug Screening Assays AntitumorTricyclic
researchProduct

Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective

2018

Antineoplastic drugs can be associated with several side effects, including cardiovascular toxicity (CTX). Biochemical studies have identified multiple mechanisms of CTX. Chemoterapeutic agents can alter redox homeostasis by increasing the production of reactive oxygen species (ROS) and reactive nitrogen species RNS. Cellular sources of ROS/RNS are cardiomyocytes, endothelial cells, stromal and inflammatory cells in the heart. Mitochondria, peroxisomes and other subcellular components are central hubs that control redox homeostasis. Mitochondria are central targets for antineoplastic drug-induced CTX. Understanding the mechanisms of CTX is fundamental for effective cardioprotection, without…

Stromal cellPhysiologymedicine.medical_treatmentTyrosine kinase inhibitorChemotherapy; HER-2 inhibitors; Oxidative/nitrosative stress; Tyrosine kinase inhibitors; Vascular endothelial growth factorReviewOxidative phosphorylation030204 cardiovascular system & hematologyMitochondrionPharmacologyChemotherapy; HER-2 inhibitors; Oxidative/nitrosative stress; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Physiology; Physiology (medical)chemotherapyHER-2 inhibitorlcsh:Physiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)tyrosine kinase inhibitorsMedicinechemotherapy HER-2 inhibitors oxidative/nitrosative stress vascular endothelial growth factor tyrosine kinase inhibitorsReactive nitrogen specieschemistry.chemical_classificationCardioprotectionReactive oxygen speciesChemotherapyCardiotoxicitylcsh:QP1-981vascular endothelial growth factorbusiness.industryOxidative/nitrosative strechemistry030220 oncology & carcinogenesisbusinessHER-2 inhibitorsoxidative/nitrosative stress
researchProduct

Noninvasive Flap Preconditioning by Foam-Mediated External Suction Improves the Survival of Fasciocutaneous Axial-Pattern Flaps in a Type 2 Diabetic …

2018

Background Advances in reconstructive surgery are leading to an increased number of flaps at risk for ischemic necrosis, because of either intrinsic (e.g., larger flap size) or extrinsic (e.g., diabetes) factors. Methods to preoperatively improve flap vascularity and limit postoperative ischemia are lacking. Noninvasive suction, using either a macrodeformational silicone cup interface (external volume expansion) or a microdeformational polyurethane foam interface (foam-mediated external volume expansion), has been shown to induce angiogenesis in tissues. The authors investigated whether the preoperative use of external volume expansion/foam-mediated external volume expansion improves flap s…

Suction (medicine)Reconstructive surgerymedicine.medical_specialtyAngiogenesisTissue ExpansionIschemiaMice ObeseMice Inbred StrainsStimulationSuctionVascular Remodeling030230 surgerySurgical FlapsDiabetes Mellitus ExperimentalNecrosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVascularitymedicineAnimalsPostoperative PeriodIschemic PreconditioningInflammationbusiness.industryGraft SurvivalHistologymedicine.diseaseSurgeryVascular endothelial growth factorDisease Models AnimalDiabetes Mellitus Type 2chemistry030220 oncology & carcinogenesisFemaleSurgerymedicine.symptombusinessPlastic and Reconstructive Surgery
researchProduct

Short‐term hypoxia promotes vascularization in co‐culture system consisting of primary human osteoblasts and outgrowth endothelial cells

2019

Prevascularization of tissue constructs before implantation has been developed as a novel and promising concept for successful implantation. Since hypoxia might induce angiogenesis, we have investigated the effects of hypoxic treatment on vascularization by using co-cultures of primary human osteoblasts (POBs) and outgrowth endothelial cells. Our results show that: (a) repeated short-term hypoxia (2% O2 for 8 hr), not long-term hypoxia (2% O2 for 24 hr), over 1 or 2 weeks, significantly enhances microvessel formation in co-cultures; (b) sustained hypoxia, not short-term or long-term hypoxia, causes cytotoxicity in mono- and co-cultures; (c) the expression of some angiogenic and inflammatory…

Time FactorsMaterials scienceCell SurvivalAngiogenesisProtein subunitmedicine.medical_treatment0206 medical engineeringBiomedical EngineeringNeovascularization Physiologic02 engineering and technologyBone tissueBiomaterialschemistry.chemical_compoundmedicineHumansRNA MessengerCytotoxicityMicrovesselCells CulturedOsteoblastsCell DeathGrowth factorMetals and AlloysEndothelial CellsHypoxia (medical)021001 nanoscience & nanotechnology020601 biomedical engineeringCell HypoxiaCoculture TechniquesUp-RegulationVascular endothelial growth factormedicine.anatomical_structurechemistryCeramics and CompositesCancer researchInflammation Mediatorsmedicine.symptom0210 nano-technologyJournal of Biomedical Materials Research Part A
researchProduct

Hypoxia-inducible factor 1Α may regulate the commitment of mesenchymal stromal cells toward angio-osteogenesis by mirna-675-5P

2017

Abstract Background aims During bone formation, angiogenesis and osteogenesis are regulated by hypoxia, which is able to induce blood vessel formation, as well as recruit and differentiate human mesenchymal stromal cells (hMSCs). The molecular mechanisms involved in HIF-1α response and hMSC differentiation during bone formation are still unclear. This study aimed to investigate the synergistic role of hypoxia and hypoxia-mimetic microRNA miR-675-5p in angiogenesis response and osteo-chondroblast commitment of hMSCs. Methods By using a suitable in vitro cell model of hMSCs (maintained in hypoxia or normoxia), the role of HIF-1α and miR-675-5p in angiogenesis and osteogenesis coupling was inv…

Transcriptional ActivationVascular Endothelial Growth Factor A0301 basic medicineCancer ResearchAngiogenesisCellular differentiationImmunologyNeovascularization PhysiologicBiology03 medical and health scienceschemistry.chemical_compoundOsteogenesisMiR-675-5pmedicineHumansImmunology and AllergyHypoxiaCells Culturedbeta CateninGenetics (clinical)TransplantationOsteoblastsMesenchymal stromal cellMesenchymal stem cellWnt signaling pathwayCell DifferentiationMesenchymal Stem CellsOsteoblastCell BiologyHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaUp-RegulationCell biologyVascular endothelial growth factorMicroRNAsVascular endothelial growth factor A030104 developmental biologymedicine.anatomical_structureGene Expression RegulationOncologyHypoxia-inducible factorschemistryRegenerative medicineImmunologyOsteoblast commitmentCytotherapy
researchProduct

Evidence for and Against Hypoxia as the Primary Cause of Tumor Aggressiveness

2003

In clinical trials, tumor hypoxia has consistently been associated with tumor aggressiveness. The evidence for an association between hypoxia and metastasis and more rapid tumor progression and death is seen in uterine cervical cancer, and sarcoma of soft tissue. Evidence is building in prostate, vulva, head and neck, and breast cancers. A major question is whether hypoxia precedes tumor aggressiveness or whether aggressive tumors incidentally are also hypoxic.

Tumor hypoxiabusiness.industryHypoxia (medical)medicine.diseaseMetastasisVulvaVascular endothelial growth factorchemistry.chemical_compoundmedicine.anatomical_structurechemistryTumor progressionProstatemedicineCancer researchSarcomamedicine.symptombusiness
researchProduct

VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart

2014

Abstract Angiogenic growth factors have recently been linked to tissue metabolism. We have used genetic gain‐ and loss‐of function models to elucidate the effects and mechanisms of action of vascular endothelial growth factor‐B (VEGF‐B) in the heart. A cardiomyocyte‐specific VEGF‐B transgene induced an expanded coronary arterial tree and reprogramming of cardiomyocyte metabolism. This was associated with protection against myocardial infarction and preservation of mitochondrial complex I function upon ischemia‐reperfusion. VEGF‐B increased VEGF signals via VEGF receptor‐2 to activate Erk1/2, which resulted in vascular growth. Akt and mTORC1 pathways were upregulated and AMPK downregulated, …

VEGF‐Bmedicine.medical_specialtyMedicine (General)AngiogenesiseducationMOUSE HEARTIschemiaVEGF-B610 Medicine & healthmTORC1ischemiaBiologyQH426-470CONTRIBUTESchemistry.chemical_compoundangiogenesisR5-920CARDIAC-FUNCTIONInternal medicinemedicineGeneticsFAILUREta318Myocardial infarctionFATTY-ACID UPTAKEREPERFUSION INJURY610 Medicine & healthProtein kinase BMYOCARDIAL HYPERTROPHYAMPKta3121medicine.diseaseCell biologyARTERIOGENESISVascular endothelial growth factorMICEEndocrinologychemistry3121 General medicine internal medicine and other clinical medicineendothelial cellMolecular Medicine3111 BiomedicineReperfusion injurymetabolism
researchProduct

In Vivo Modulation of Angiogenesis and Immune Response on a Collagen Matrix via Extracorporeal Shockwaves

2020

The effective management of tissue integration and immunological responses to transplants decisively co-determines the success of soft and hard tissue reconstruction. The aim of this in vivo study was to evaluate the eligibility of extracorporeal shock wave therapy (ESWT) with respect to its ability to modulate angiogenesis and immune response to a collagen matrix (CM) for tissue engineering in the chorioallantoic membrane (CAM) assay, which is performed with fertilized chicken eggs. CM were placed on the CAM on embryonic development day (EDD) 7

Vascular Endothelial Growth Factor A0301 basic medicineAngiogenesismedicine.medical_treatmentNitric Oxide Synthase Type IIChick EmbryoChorioallantoic Membranelcsh:ChemistryNeovascularizationangiogenesischemistry.chemical_compoundmacrophage response0302 clinical medicineTissue engineeringlcsh:QH301-705.5Spectroscopyoral inflammationTissue Scaffoldsvascular endothelial growth factorGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorChorioallantoic membraneExtracorporeal shockwave therapyCollagenmedicine.symptomchorioallantoic membrane assayNeovascularization PhysiologicArticleCatalysisAvian ProteinsInorganic ChemistryAndrology03 medical and health sciencesImmune systemIn vivomatrix metalloproteasesmucoderm®medicineAnimalsddc:610Physical and Theoretical Chemistrymucoderm<sup>®</sup>Molecular BiologyTissue Engineeringbusiness.industryOrganic Chemistrycollagen matrix030206 dentistryextracorporeal shockwave therapyHypoxia-Inducible Factor 1 alpha SubunitMatrix Metalloproteinases030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistrybusiness
researchProduct